Cisplatin-Rich Polyoxazoline-Poly(aspartic acid) Supramolecular Nanoparticles

Area of Science:

• Materials Science
• Nanotechnology
• Drug Delivery

Background:

• Developing effective drug delivery systems for cancer therapy is crucial.
• Cisplatin is a widely used chemotherapy drug with limitations in delivery and side effects.
• Supramolecular chemistry offers novel strategies for nanoparticle construction and drug incorporation.

Purpose of the Study:

• To construct cisplatin-rich supramolecular nanoparticles using supramolecular inclusion interactions.
• To evaluate the physicochemical properties, stability, and anticancer efficacy of these nanoparticles.
• To assess the in vivo tumor targeting capability of the nanoparticles.

Main Methods:

• Synthesis of adamantyl (Ad)-terminated poly(aspartic acid) (Ad-P(Asp)) and β-cyclodextrin (β-CD)-terminated poly(2-methyl-2-oxazoline).
• Formation of supramolecular nanoparticles via β-CD/admantane inclusion complexation and cisplatin coordination.
• In vitro cell proliferation inhibition assays using H22 cancer cells.
• In vivo near-infrared fluorescence imaging of tumor-bearing mice.

Main Results:

• Spherical cisplatin-rich supramolecular nanoparticles were successfully constructed.
• The nanoparticles exhibited a high cisplatin-loading content of 53% and good stability.
• Effective inhibition of H22 cancer cell proliferation was observed.
• Demonstrated effective in vivo tumor targeting in a mouse model.

Conclusions:

• Supramolecular inclusion interactions provide an efficient method for creating cisplatin-rich nanoparticles.
• These nanoparticles show significant potential as a targeted drug delivery system for cancer therapy.
• Further investigation into their therapeutic efficacy and safety is warranted.